Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vercirnon (Traficet-EN) 是可口服的选择性 CCR9拮抗剂,可抑制 CCR9 介导的 Molt-4 细胞上 Ca2+移动和趋化性,用于炎症性肠病的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 863 | 现货 | ||
5 mg | ¥ 2,130 | 现货 | ||
10 mg | ¥ 3,270 | 现货 | ||
25 mg | ¥ 5,350 | 现货 | ||
50 mg | ¥ 7,530 | 现货 | ||
100 mg | ¥ 9,870 | 现货 | ||
500 mg | ¥ 19,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,180 | 现货 |
产品描述 | Vercirnon (Traficet-EN) is a selective and potent antagonist of CCR9 (IC50: 10 nM). It is also used in the research of inflammatory bowel diseases. |
靶点活性 | CCR9:10 nM |
体外活性 | Vercirnon is also a potent inhibitor of CCL25-induced Molt-4 chemotaxis (IC50: 3.5 ± 0.3 nM). Vercirnon inhibits CCL25-induced calcium mobilization (IC50: 5.4 ± 0.7 nM). Vercirnon inhibits the chemotaxis of Baf-3/CCR9A cells as well as Baf-3/CCR9A cells (IC50s: 2.8 ± 1.1 nM and 2.6 ± 0.7 nM, respectively). Vercirnon potently inhibits CCL25-induced chemotaxis (IC50: 6.8 ± 1.7 nM in the buffer) and exhibits inhibition on RA-cultured cell CCL25-medidated chemotaxis in 100% human AB serum (IC50: 141 ± 13 nM). Vercirnon shows inhibitory activity against Molt-4 migration (IC50: 33.4 ± 1.3 nM in 100% human AB serum). Vercirnon suppresses the binding of [3H] CCX807 to Molt-4 cells (IC50: 6 nM) [1]. |
体内活性 | Vercirnon (50?mg/kg c.c. twice daily) blocks the colitis-associated weight loss inherent in the mdr1a?/? model and also abrogates growth arrest in the colitis mdr1a ?/? mice. Vercirnon (10, 50 mg/kg twice daily) protects from the severe inflammation associated with TNF-α overexpression in the TNFΔARE Mouse Model [2]. |
别名 | CCX282-B, 维塞诺, GSK-1605786, Traficet-EN |
分子量 | 444.93 |
分子式 | C22H21ClN2O4S |
CAS No. | 698394-73-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22.25 mg/mL (50 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2475 mL | 11.2377 mL | 22.4754 mL | 56.1886 mL |
5 mM | 0.4495 mL | 2.2475 mL | 4.4951 mL | 11.2377 mL | |
10 mM | 0.2248 mL | 1.1238 mL | 2.2475 mL | 5.6189 mL | |
20 mM | 0.1124 mL | 0.5619 mL | 1.1238 mL | 2.8094 mL | |
50 mM | 0.045 mL | 0.2248 mL | 0.4495 mL | 1.1238 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vercirnon 698394-73-9 Immunology/Inflammation Microbiology/Virology CCR chemotaxis CCX282-B bioavailable 维塞诺 oral inhibit GSK-1605786 inflammatory Inhibitor bowel GSK 1605786 chemokine CC chemokine receptor Traficet-EN GSK1605786 disease inhibitor